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Simple Summary: Immunotherapy is an effective treatment that harnesses the immune system to
fight cancer. Drugs such as immune checkpoint inhibitors have demonstrated efficacy in the treatment
of advanced melanoma. However, the optimal duration of treatment is not well established. The aim
of our retrospective study was to analyse the outcomes of patients who have stopped immunotherapy
treatment for advanced melanoma after durable disease control. Furthermore, we assessed circulating
tumour DNA (ctDNA), which is shed from the tumour into the bloodstream, to determine its validity
as a predictive biomarker of disease progression after treatment was stopped. We demonstrated that
stopping treatment after durable disease control results in excellent short- to medium-term prognosis
and ctDNA present at the time of stopping treatment is a strong predictor of disease recurrence.
Abstract: Immunotherapy is an important and established treatment option for patients with advanced
melanoma. Initial anti-PD1 trials arbitrarily defined a two-year treatment duration, but a shorter
treatment duration may be appropriate. In this study, we retrospectively assessed 70 patients who
stopped anti-PD1 therapy in the absence of progressive disease (PD) to determine clinical outcomes.
In our cohort, the median time on treatment was 11.8 months. Complete response was attained at time
of anti-PD1 discontinuation in 61 (87%). After a median follow up of 34.2 months (range: 2–70.8) post
discontinuation, 81% remained disease free. Using ddPCR, we determine the utility of circulating
tumour DNA (ctDNA) to predict progressive disease after cessation (n = 38). There was a significant
association between presence of ctDNA at cessation and disease progression (p = 0.012, Fisher’s exact
test) and this conferred a negative and positive predictive value of 0.82 (95% CI: 0.645–0.930) and 0.80
(95% CI 0.284–0.995), respectively. Additionally, dichotomised treatment-free survival in patients
with or without ctDNA at cessation was significantly longer in the latter group (p < 0.001, HR: 0.008,
95% CI: 0.001–0.079). Overall, our study confirms that durable disease control can be achieved with
cessation of therapy in the absence of disease progression and undetectable ctDNA at cessation was
associated with longer treatment-free survival.
Keywords: melanoma; immune checkpoint inhibitors; anti-PD1; complete response; therapy cessation;
ctDNA; biomarkers
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1. Introduction
The treatment options for metastatic melanoma have improved dramatically with the
advent of novel therapies including checkpoint inhibitors, leading to substantial improvement
in progression-free survival (PFS) and overall survival (OS), heralding a new era in melanoma
treatment [1,2]. Current first-line immunotherapy options in advanced melanoma include either
anti-PD1 (anti programmed cell death receptor 1) antibody monotherapy or the combination of
ipilimumab (anti CTLA4 antibody—Cytotoxic T lymphocyte-associated protein 4) and nivolumab
(anti-PD1). The immune checkpoint inhibitor pembrolizumab received FDA approval in 2014 for
patients with advanced melanoma [3]. Pembrolizumab is an engineered humanised IgG4 monoclonal
antibody that regulates T cell activation by blocking the programmed cell death protein 1 (PD1) [4].
Unfortunately, only a minority of patients experience the dramatic benefits of immunotherapy
due to primary and acquired resistance [5]. Complete response (CR) occurs in up to 20% of metastatic
melanoma patients treated with anti-PD1 monotherapy [2]. The duration of immunotherapy treatment
in responding patients has been arbitrarily set at 2 years but optimal duration remains unknown [6,7].
Although anti-PD1 monotherapy is a relatively well-tolerated treatment, there remains a risk of toxicity,
and little is known about the long-term effects. In addition, ongoing therapy impacts patient quality of
life and health care budgets. Dealing with these burgeoning costs is a major challenge for the health
system and considerable research is being conducted to find biomarkers to identify responders to
appropriately tailor treatment choices. In the meantime, identifying patients that can safely undergo
a shorter treatment duration and save health care dollars is paramount.
Circulating tumour DNA (ctDNA), released into plasma from apoptosing or necrotic tumour cells,
has emerged as a useful biomarker for assessment of response to therapy in various cancers [8–10].
In melanoma, we and others have shown the clinical validity of using ctDNA for tracking response
to therapy and prognostication [11–15]. Baseline ctDNA levels have been shown to be directly
associated with radiological tumour burden and inversely associated with response and PFS [16].
Furthermore, it has been shown that undetectable ctDNA at baseline or within eight weeks of
commencing anti-PD1 immunotherapy is an independent predictor of response and PFS [12,15].
Nonetheless, there have been no studies to date to investigate ctDNA as an indicator for safe early
cessation of therapy and durable treatment-free survival (TFS). Such a test would be especially useful
in difficult or equivocal radiological evaluations where tissue biopsy is not feasible.
Here, we retrospectively assessed and report the clinical outcomes of 70 patients who stopped
anti-PD1 therapy in the absence of progressive disease (Figure 1). In addition, we explore the potential
of ctDNA to determine safe cessation of therapy and detection of early recurrence.
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Figure 1. Schema of the 70 patients treated with anti-PD1 therapy and ceased treatment in the absence
of disease progression.

2. Results
2.1. Patient Description
Seventy patients were identified who ceased pembrolizumab after achieving durable disease
control (stable disease (SD), partial response (PR) or complete response (CR)) without evidence of
progressive disease at time of treatment cessation. Baseline demographics (n = 70) are shown in Table 1.
Median age was 71 (29–91) years. Most patients had M1c (44%) disease (AJCC eighth edition) with
normal LDH levels (70%) and less than three metastatic sites of disease (77%). Half of the cohort had
received prior therapy including chemotherapy (7%), ipilimumab (21%) and targeted therapy (19%).
BRAF V600 mutations were present in 14 patients (20%), with 13 having received and progressed on
prior BRAF inhibitor treatment. Only seven patients (10%) had intracranial disease involvement at the
time of treatment initiation.
Table 1. Patient demographics of the study cohort prior to immunotherapy initiation (n = 70).
Demographic Variables

Number of Patients (%)

Age (years)
Median
Range

71
29–91

Male
Female

49 (70)
21 (30)

0
1
≥2
Stage at commencement of anti-PD1
M1a
M1b
M1c
M1d

53 (75)
11 (16)
6 (9)

Gender

ECOG

20 (29)
12 (17)
31 (44)
7 (10)
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Table 1. Cont.
Demographic Variables
Number of metastatic sites
<3
>3
Lines of prior therapy
0
≥1
Prior systemic therapy
Chemotherapy (DTIC/Fotemustine)
BRAFi or BRAF/MEKi
Ipilimumab
BRAF V600 mutation
Yes
No
LDH prior to anti-PD1 therapy
<ULN
>1×ULN
>2×ULN
Unknown
Brain metastases
Absent
Present

Number of Patients (%)
54 (77)
16 (23)
36 (51)
34 (49)
5 (7)
13 (19)
15 (21)
14 (20)
56 (80)
49 (70)
13 (19)
3 (4)
5 (7)
63 (90)
7 (10)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; AJCC, American Joint Committee on Cancer (8th edition);
DTIC, Dacarbazine; LDH, lactate dehydrogenase; ULN, upper limit of normal.

Median treatment duration was 11.8 (range: 3–33) months, with 38 patients (54%) having less than
12 months of treatment. A total of 61 out of the 70 (87%) patients attained CR. The median duration
of therapy for patients who achieved CR was 11.7 months (range: 3–28), whilst the median duration
of therapy for patients attaining PR/SD was 24.7 months (range: 5–33). The median follow-up since
treatment cessation was 34.2 months (range: 2–70.8) (Table 2, Figure 2). Median PFS and OS for the
cohort have not yet been reached (Figure 3A,B). Twelve patients (17%) ceased due to immune-related
toxicity (n = 9) or intolerance (n = 3). Reasons for treatment cessation due to toxicity included
Guillain–Barre Syndrome (n = 1), colitis (n = 1), hepatitis (n = 1), pneumonitis (n = 2), skin toxicity
(n = 3) and pancreatitis (n = 1).

Figure 2. Swimmer plot indicating time on anti-PD1 therapy, progression-free survival and overall
survival following disease progression.
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Table 2. Outcome of anti-PD1 antibody treatment (n = 70).
Variable
Treatment duration (months)
Median
Range
Response at cessation
Complete Response
Partial Response
Stable Disease
Time to BOR (months)
Median
Range
Time to CR (n= 61) (months)
Median
Range
PD post cessation
No
Yes
Follow up post cessation (months)
Median
Range
Treatment free survival (months)
Median
Range
Time to PD after cessation (n=13) (months)
Median
Range
PFS (months)
Median
Range
OS (months)
Median
Range

N (%)
11.8
3–33
61 (87)
6 (8.6)
3 (4.3)
5
1–29
5
1–29
57 (81)
13 (19)
34.2
2–70.8
Not reached
2–70.2
11.1
2.2–27.8
Not reached
6–81.8
Not reached
6.3–81.8

Figure 3. Survival outcomes of melanoma patients that ceased anti-PD1 immunotherapy. Kaplan–Meier
probability curves for progression-free survival (PFS, A) and overall survival (OS, B) for the total cohort
of patients who discontinued treatment in the absence of disease progression (median PFS and OS
not yet reached. (C) Dichotomised treatment-free survival (TFS) of patients detectable or undetectable
ctDNA at cessation (p < 0.001, log-rank test, median TFS not yet reached).

2.2. Progressive Disease in the Whole Cohort
Thirteen patients (19%) developed progressive disease following cessation of therapy. Disease
progression occurred with the following best overall response (BOR) distribution: SD: 2/3, PR: 2/6 and
CR: 9/61. The median time to disease progression following cessation of therapy for all patients was
12.1 months (range: 2.2–27.2). The median time on therapy for patients with CR who subsequently
recurred was similar to the whole cohort at 11.7 months. With respect to the baseline characteristics of
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patients with PD, 12/13 had less than three metastatic sites of disease, 8 had M1c disease, none had
brain metastases prior to treatment initiation and two patients had an ECOG greater than 1.
2.3. ctDNA in Patients Ceasing Anti-PD1 Therapy
We analysed ctDNA levels at the time of immunotherapy cessation in the subgroup of patients
with assessable blood samples (Figure 1). A total of 38 patients included in the study had a traceable
mutation and a blood sample collected within 16 weeks prior to or after anti-PD1 immunotherapy
cessation (Table S2). A total of 10/38 patients developed disease progression whilst the rest of the
cohort (28/38) sustained response post immunotherapy cessation. The mutations identified in the
patients’ tumours and used for ctDNA assessment are listed in Tables S1 and S2. Five of the 38 patients
had detectable ctDNA at the time of treatment cessation but only 4 of these patients went on to develop
progressive disease within 2.5–14.2 months (median: 8.4 months) following cessation (BOR; CR = 2/4,
PR = 2/4). Two of the five patients with detectable ctDNA (MM176 and MM295) had rising ctDNA
levels prior to cessation, suggesting treatment resistance despite ongoing radiological response at
cessation (Figure S1A,B). The other six patients with radiological progression had CR as their best
response, undetectable ctDNA at cessation and developed disease progression within 4.7–21.8 months
(median: 15 months). One patient with detectable ctDNA at cessation did not develop disease
progression at time of analysis.
Of the 28 of 38 patients analysed for ctDNA who did not progress, 26 patients achieved CR, 1 had
PR and 1 SD at cessation of therapy. Plasma ctDNA was undetectable in 27 of these 28 (96%) patients,
with only 1 patient having detectable ctDNA at cessation (Table 3). CtDNA became undetectable
83 weeks after cessation and the patient remained in CR until last follow up at 45 months after cessation
(Figure S1C).
Table 3. Plasma ctDNA results at time of cessation relative to clinical outcome.

ctDNA detectable
ctDNA undetectable
Total

Ongoing Response (n)

Disease Progression (n)

Total (n)

1
27
28

4
6
10

5
33
38

As shown in Table 3, the rate of detectable ctDNA without disease progression or false-positive
results was low, with a specificity of 0.96. However, the rate of undetectable ctDNA in patients who
developed disease progression or false negatives was much higher, resulting in a poor sensitivity of 0.33.
Detectable ctDNA at cessation conferred a high relative risk of relapse (RR: 4, 95% CI: 1.88–10.26)
and a positive predictive value of 0.80 (95% CI 0.283–0.995). By contrast, undetectable ctDNA at
cessation was significantly associated with a low risk of relapse by Fisher’s exact test (p = 0.012,
Table 3), with a negative predictive value of 0.82 (95% CI: 0.645–0.930). Additionally, absence of ctDNA
at cessation was significantly associated with longer treatment-free survival (p < 0.0001, HR: 0.007,
CI 95% (0.001–0.786). The median treatment-free interval for patients with detectable ctDNA at time
of treatment cessation was 10 months but was not reached in patients with undetectable ctDNA
(Figure 3C).
3. Discussion
In this study, we describe a real-world local experience and outcomes of melanoma patients who
stopped anti-PD1 therapy in the absence of disease progression, contributing to the growing body of
research demonstrating durable response to immunotherapy [17–19]. Furthermore, we have a subgroup
of these patients to determine the utility of ctDNA in predicting recurrence following cessation.
Our study is the first to evaluate ctDNA in the context of treatment cessation in advanced melanoma.
The arbitrary treatment duration of immunotherapy for advanced melanoma patients imposes
clinical and financial toxicity on patients. There is increasing interest in determining the optimal
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treatment duration for immunotherapy in advanced melanoma. Several clinical trials have commenced
recruitment to address this question (STOP GAP NL65512.078.18, Safe Stop NTR7502). Two pivotal
studies, Checkmate 067 and Keynote 006 evaluated different lengths of treatment duration; Keynote 006
mandated a maximum of 2 years of treatment, whilst Checkmate 067 did not define a maximum
treatment period [20,21]. In a four-year survival update for Checkmate 067, one-quarter of patients who
received anti-PD1 monotherapy still remained on treatment [22]. However, at five years, this dropped
to 7% without any significant change in overall survival [21].
With over 50% of patients in our cohort having less than 12 months of treatment and the recurrence
rate remaining comparable to Keynote 006, it raises the possibility of safe early treatment cessation
once CR has been confirmed. Our cohort of 70 patients certainly further confirms that beyond clinical
trials, patients who attain complete response to anti-PD1 monotherapy have an excellent prognosis in
the short to medium term and this gives further credence to the concept of stopping treatment early
following CR [7].
With respect to the whole cohort, our data are comparable to other immunotherapy cessation
reports [17,19,23,24]. The median time on treatment for our cohort was 11.8 months (range: 3–33),
with a similar median treatment time for patients who achieved a complete response (11.7 months).
This is similar to the recently published largest real-world cohort of 187 patients who stopped treatment
in the absence of disease progression with a median time on therapy of 12 months [17]. In our
study 38 patients (54%) had less than 12 months of treatment. In those who had disease progression,
the median time on therapy was similar to the whole cohort at 12.4 months. However, 33% had
6 months or less of treatment. This is concordant with other studies showing treatment less than
6 months has been shown to be associated with a higher risk of progression [17].
With a median of 34 months follow up after treatment cessation, progression occurred in 19%
of our cohort. This recurrence rate is comparable to other studies which report progressive disease
in 11–23% of patients stopping treatment [17,19,23,24]. It appears that if 6–24 months of therapy is
completed, the risk of progression is similar, regardless of the duration of therapy [17]. Based on
clinical data from multiple treatment cessation studies, albeit post hoc or retrospective, it is becoming
clearer that the risk of recurrence following CR is in the order of 13–24% and the rate of recurrence
does not appear to be affected by treatment duration [2,17,19].
Undetectable ctDNA prior to and/or after cessation appears to strongly predict lack of recurrence
and detectable ctDNA moderately predicts relapse in these patients. Thus, ctDNA in this population
can become a useful adjunct to monitoring with standard imaging criteria. Furthermore, a detectable
ctDNA level following treatment cessation predicts disease progression and shorter treatment-free
intervals, and should, therefore, prompt radiological surveillance and close observation.
Patients with PR or SD as their best response have a higher risk (14–32%) of developing disease
progression following treatment cessation [2,17,24]. The rate of progression is also high in our SD/PR
(4/9, 44%) vs. CR (9/61, 15%) group but the low number of the former is not sufficient to make definitive
conclusions about the risk of disease progression in this group. With the higher rates of recurrence in
patients with PR/SD, it is clear that guidelines for the duration of treatment are particularly needed in
this population. We have demonstrated that serial monitoring of ctDNA around the time of cessation
in this population may provide valuable information about the disease kinetics, assisting in treatment
decisions. For example, rising ctDNA levels despite ongoing radiological response could guide early
treatment cessation and switch. Alternatively, ctDNA may be used to guide treatment length in
PR/SD patients with declining or undetectable ctDNA levels. For these patients, therapy could be
stopped with the potential inclusion of a biopsy of any residual radiologic disease for confirmation
of pathological response. Given the potential pharmacoeconomic benefits of this approach, we feel
prospective trials on treatment cessation should incorporate plasma ctDNA testing. This will be useful
to validate ctDNA as an added biomarker for guiding treatment cessation in patients with partial
response or stable disease.
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While our study does provide some evidence of the potential of ctDNA as a disease status
biomarker, we acknowledge sampling error as a significant caveat to the use of ctDNA in monitoring
post therapy cessation in patients with CR. Given the low disease burden in the cessation cohort,
the rate of false-negative results in those with undetectable levels was high. While our use of digital
PCR provides a high technical sensitivity for analysis of ctDNA, this targeted approach is highly
sensitive to sampling error at such low ctDNA concentrations [10,25]. In the analysis of ctDNA in
our cohort, the specificity to detect relapse was high, but the sensitivity was disappointingly low.
Sensitivity may be enhanced with the use of larger plasma volumes and the monitoring of multiple
mutations for each case [26]. It has been demonstrated that ctDNA can certainly be valuable in minimal
residual disease [27] and therefore further studies to evaluate the sensitivity and specificity in this post
treatment setting are warranted to progress its integration into clinical use.
4. Materials and Methods
4.1. Patients
Seventy patients treated for stage IV melanoma with intravenous anti-PD1 monotherapy
(Pembrolizumab, 2mg/kg every three weeks) at Sir Charles Gairdner Hospital in Perth, Western Australia
between August 2013 and July 2019 were retrospectively evaluated (Figure 1). Patients were included
if they ceased anti-PD1 monotherapy due to CR or had treatment for two years and stopped with
a durable response (SD or PR). Patients were also included if they ceased treatment due to toxicity but
had no evidence of disease progression at cessation of therapy. There was no defined minimum duration
of treatment included. Written informed consent was obtained from all patients under approved
Human Research Ethics Committee protocols from Edith Cowan University (No. 11543 (9 July 2014)
and No. 18957 (14 May 2018)) and Sir Charles Gairdner Hospital (No. 2007-123 (1 October 2007),
No. 2013-246 (5 June 2014), RGS0000003289 (24 June 2020)) in compliance with the Declaration of
Helsinki. Experiments were performed in accordance with institutional and national guidelines
and regulations.
Demographic and clinical data including age, gender, Eastern Cooperative Oncology Group
(ECOG) performance status, disease stage, baseline LDH and presence of brain metastases were
collected. The duration of pembrolizumab therapy, time to BOR, recurrence and sites of progression
were assessed. Subsequent treatments and response were also collected. Tumour responses during
and at completion of treatment were assessed radiologically by computer tomography (CT) and/or
positron emission tomography (PET) scans by Response Evaluation in Solid Tumors (RECIST 1.1) or
immune-related Response Criteria (irRC) and classified as having a complete response, partial response
or stable disease. CR was defined as an absence of radiological disease or a negative biopsy of
residual tissue.
4.2. Blood Collection and ctDNA Analysis
Blood samples were collected using a EDTA vacutainer or cell-free DNA BCT tubes (Streck, La Vista,
NE, USA). Plasma was separated from whole blood as previously described and stored at 4 ◦ C [27,28].
Cell-free DNA (cfDNA) was extracted from 5 mL of plasma using the QIAamp Circulating Nucleic
Acid Kit (Qiagen, Hilden, Germany). DNA samples were stored (−80 ◦ C) until analysis. The ctDNA
was quantified by droplet digital PCR (ddPCR).
Trackable mutations were identified in 45/49 (92%) patients with samples available via standard
pathology protocols or using a customised melanoma NGS panel (Illumina, San Diego, CA, USA),
as described by Calapre et al. [29]. Commercially available and/or customised probes were used to
analyse ctDNA by ddPCR [30]. Amplifications were carried out in a 20 µL reaction containing 1×
droplet PCR supermix, 250 nM of each probe, 900 nM primers and 5 or 8 µL cfDNA. Droplets were
generated and analysed using the QX200 system (Bio-Rad, Hercules, CA, USA). The threshold for each
assay used for ctDNA detection was previously reported by Calapre et al. [29] and Marsavela et al. [31].
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A positive control, a healthy control and a no template control were included in each run. Only tests
providing more than 10,000 droplets were used for analysis. Quantification results were presented in
copies of ctDNA per mL of plasma. All samples were tested in triplicate.
4.3. Statistics
Median OS, PFS and TFS were calculated using the Kaplan–Meier method and compared using
the log-rank test. Correlation between ctDNA detectability at cessation and disease progression,
with corresponding p-values, positive predictive values (PPV) and negative predictive values (NPV)
were calculated using Fisher’s exact test. All statistical analyses were performed using GraphPad
Prism version 8 (GraphPad Software Inc., San Diego, CA, USA) and SPSS version 25 (IBM, Armonk,
NY, USA).
5. Conclusions
Our study provides additional evidence that cessation of treatment in the context of complete
response is durable. Given the economic toxicity, side effects and impact on quality of life of ongoing
treatment, it is important to determine optimal treatment duration and establish biomarkers to guide
treatment cessation decisions. Plasma ctDNA at cessation appears to predict recurrence. However,
its clinical utility is still limited by its capacity to reliably detect residual disease. As pre-analytical
conditions and methodology improve, we anticipate that ctDNA could ultimately be an important
adjunct to treatment cessation decisions.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/11/3486/s1,
Figure S1A–C: Graphical representation of clinical outcomes and corresponding ctDNA over time; Table S1:
Detailed list of mutation types identified across the cohort; Table S2; Detailed list of blood collection timepoints
and outcome relative to cessation.
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